申请人:Tatani Kazuya
公开号:US08680120B2
公开(公告)日:2014-03-25
A compound (I) of the present invention, which has an EP1 receptor antagonism:
[wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
本发明提供了一种具有EP1受体拮抗作用的化合物(I):[其中,A代表苯环或类似物;Y1代表C1-6烷基;Y2代表单键或类似物;R1代表氢原子,C1-6烷基或类似物;R2代表苯基,可以有取代基,也可以是5-成员芳香族杂环环,可以有取代基,也可以是6-成员芳香族杂环环,可以有取代基或类似物;R3代表卤素原子,C1-6烷氧基或类似物;R4代表氢原子或类似物;R5代表氢原子或类似物]或其药学上可接受的盐。此外,本发明的化合物(I)可以用作治疗或预防下尿路症状,特别是膀胱过度活动症的各种症状的药物。